Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone510-748-3200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$547.41 million
Profitability
Miscellaneous
Employees2,200
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable
Penumbra (NYSE:PEN) Frequently Asked Questions
What is Penumbra's stock symbol?
Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."
How were Penumbra's earnings last quarter?
Penumbra Inc (NYSE:PEN) posted its earnings results on Tuesday, February, 25th. The company reported $0.22 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.18 by $0.04. The company earned $145.26 million during the quarter, compared to the consensus estimate of $141.64 million. Penumbra had a net margin of 8.85% and a return on equity of 7.86%. View Penumbra's Earnings History.
When is Penumbra's next earnings date?
What guidance has Penumbra issued on next quarter's earnings?
Penumbra updated its FY 2020
After-Hours earnings guidance on Tuesday, February, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $635-645 million, compared to the consensus revenue estimate of $651.96 million.
What price target have analysts set for PEN?
7 brokers have issued 12-month price targets for Penumbra's shares. Their forecasts range from $180.00 to $200.00. On average, they anticipate Penumbra's share price to reach $191.40 in the next year. This suggests a possible upside of 9.5% from the stock's current price. View Analyst Price Targets for Penumbra.
What is the consensus analysts' recommendation for Penumbra?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Penumbra.
Has Penumbra been receiving favorable news coverage?
Media headlines about PEN stock have trended extremely negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Penumbra earned a daily sentiment score of -4.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Penumbra.
Who are some of Penumbra's key competitors?
Some companies that are related to Penumbra include Teleflex (TFX), Insulet (PODD), Novocure (NVCR), ABIOMED (ABMD), Hill-Rom (HRC), Haemonetics (HAE), Globus Medical (GMED), Tandem Diabetes Care (TNDM), Integra Lifesciences (IART), ICU Medical (ICUI), Nevro (NVRO), NuVasive (NUVA), Cantel Medical (CMD), Merit Medical Systems (MMSI) and Irhythm Technologies (IRTC).
What other stocks do shareholders of Penumbra own?
Who are Penumbra's key executives?
Penumbra's management team includes the folowing people:
- Mr. Adam Elsesser, Co Founder, Chairman, CEO & Pres (Age 57)
- Dr. Arani Bose, Co-Founder, Chief Innovator and Director (Age 57)
- Mr. Sridhar N. Kosaraju, CFO and Head of Strategy (Age 41)
- Ms. Lynn Rothman, Chief Bus. Officer and Exec. VP (Age 58)
- Mr. Daniel Donen Davis, Chief Commercial Officer (Age 41)
Who are Penumbra's major shareholders?
Penumbra's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), William Blair Investment Management LLC (3.49%), Baillie Gifford & Co. (2.79%), Alliancebernstein L.P. (2.54%), State Street Corp (2.32%) and Partner Fund Management L.P. (1.20%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Coyne David, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View Institutional Ownership Trends for Penumbra.
Which major investors are selling Penumbra stock?
PEN stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Lord Abbett & CO. LLC, Alliancebernstein L.P., Baillie Gifford & Co., Russell Investments Group Ltd., Landscape Capital Management L.L.C., Point72 Asset Management L.P. and State Street Corp. Company insiders that have sold Penumbra company stock in the last year include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju and Thomas Wilder. View Insider Buying and Selling for Penumbra.
Which major investors are buying Penumbra stock?
PEN stock was acquired by a variety of institutional investors in the last quarter, including Barclays PLC, Goldman Sachs Group Inc., William Blair Investment Management LLC, Columbus Circle Investors, New York State Common Retirement Fund, Franklin Resources Inc., Cubist Systematic Strategies LLC and Nicholas Investment Partners LP. View Insider Buying and Selling for Penumbra.
How do I buy shares of Penumbra?
Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Penumbra's stock price today?
One share of PEN stock can currently be purchased for approximately $174.75.
How big of a company is Penumbra?
Penumbra has a market capitalization of $6.10 billion and generates $547.41 million in revenue each year. The company earns $6.60 million in net income (profit) each year or $0.98 on an earnings per share basis. Penumbra employs 2,200 workers across the globe.View Additional Information About Penumbra.
What is Penumbra's official website?
How can I contact Penumbra?
Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected]
MarketBeat Community Rating for Penumbra (NYSE PEN)
MarketBeat's community ratings are surveys of what our community members think about Penumbra and other stocks. Vote "Outperform" if you believe PEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
